ASCO Presentations on PGx Melanoma Drugs Portend Crowded Market for BRAF-Mutated Tumors | GenomeWeb

Originally published June 5.

CHICAGO – Roche's personalized melanoma drug Zelboraf (vemurafenib) – the first BRAF inhibitor to enter the market and one of the few drugs to significantly improve survival in patients with advanced disease – is likely to face significant competition in coming years from next-generation agents that will attempt to mirror or improve upon the agent's efficacy and safety against skin cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.